Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia

Guo-Rui Ruan; Ya-Zhen Qin; Shan-Shan Chen; Jin-Lan Li; Xi Ma; Yan Chang; Ya-Zhe Wang; Jia-Yu Fu; Yan-Rong Liu

doi:10.1016/j.leukres.2005.12.028

Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia

Leuk Res. 2006 Sep;30(9):1159-65. doi: 10.1016/j.leukres.2005.12.028. Epub 2006 Feb 28.

Authors

Guo-Rui Ruan¹, Ya-Zhen Qin, Shan-Shan Chen, Jin-Lan Li, Xi Ma, Yan Chang, Ya-Zhe Wang, Jia-Yu Fu, Yan-Rong Liu

Affiliation

¹ Institute of Hematology and People's Hospital, Peking University, 11 Xi-zhi-men South Street, Beijing 100044, China.

PMID: 16507320
DOI: 10.1016/j.leukres.2005.12.028

Abstract

To clarify whether expression of the programmed cell death 5 (PDCD5) gene in leukemic cells is abnormal, real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) was used to examine its expression in marrow cells from leukemia patients. We found lower PDCD5 in both AML and CML marrow cells than in normal donor marrow cells. A negative correlation was found between relative levels of PDCD5 and BCR/ABL expression in all CML patients and in CML patients in the advanced phase. Treatment with the ABL tyrosine kinase inhibitor Imatinib mesylate increased PDCD5 expression in K562 and MEG-01 cells. These findings suggest that abnormal expression of PDCD5 in leukemia may be involved in the pathomechanism of AML and CML.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Apoptosis Regulatory Proteins / biosynthesis*
Apoptosis Regulatory Proteins / genetics
Benzamides
Bone Marrow Cells / metabolism
Bone Marrow Cells / pathology
Female
Fusion Proteins, bcr-abl / antagonists & inhibitors
Fusion Proteins, bcr-abl / biosynthesis
Fusion Proteins, bcr-abl / genetics
Gene Expression Regulation, Leukemic* / drug effects
Humans
Imatinib Mesylate
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / metabolism*
Leukemia, Myeloid, Acute / pathology
Male
Neoplasm Proteins / biosynthesis*
Neoplasm Proteins / genetics
Piperazines / administration & dosage
Piperazines / pharmacology
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / pharmacology
Pyrimidines / administration & dosage
Pyrimidines / pharmacology

Substances

Apoptosis Regulatory Proteins
Benzamides
Neoplasm Proteins
PDCD5 protein, human
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl